We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Fresenius SE and Company KGaA (PK) | USOTC:FSNUY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.112 | -1.48% | 7.4405 | 7.32 | 7.63 | 7.53 | 7.4405 | 7.53 | 44,836 | 21:23:30 |
From Jun 2021 to Jun 2024
By Cecilia Butini
Stephan Sturm, chief executive officer of Fresenius SE & Co. KGaA, said in an interview published on the company's website on Tuesday that a sale of Fresenius Medical Care isn't on the up for consideration.
Mr. Sturm said the business's outlook remains positive despite being hit hard by the pandemic. Concerning the company as a whole, management continues to expect healthy growth in sales and earnings this year despite continuing challenges from the pandemic, supply-chain issues and the war in Ukraine, he said.
"We do not have to divest FMC to finance growth in other business segments," the executive said.
Regarding Fresenius' presence in Russia, the executive added that a complete pullout from the country isn't an option as the company is standing by its effort to provide medical care to all people.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
June 07, 2022 12:38 ET (16:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Fresenius SE and Company... (PK) Chart |
1 Month Fresenius SE and Company... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
